Shandong Xinhua Pharmaceutical Co., Ltd. (00719): Abnormal fluctuations in A-share stock trading There is no information disclosed in the previous period that needs to be corrected or added

Zhitongcaijing · 1d ago

Zhitong Finance App News, Shandong Xinhua Pharmaceutical Co., Ltd. (00719) issued an announcement. The closing price deviation value of Shandong Xinhua Pharmaceutical Co., Ltd. (“Company”) reached 20% for three consecutive trading days on September 18, September 21, and September 22, 2026. According to the relevant regulations of the Shenzhen Stock Exchange, this is an abnormal fluctuation in stock trading.

In response to abnormal fluctuations in the company's stock, the company has verified the relevant matters. The relevant situation is explained as follows: 1. After verification, there are no corrections or additions to the information disclosed by the company in the early stages. 2. The Company has found no recent public media reports that may or have had a significant impact on the trading price of the Company's stock. 3. There have been no major changes in the company's business situation and internal and external business environment recently. 4. On September 21, 2026, the company disclosed the “Notice on Obtaining a Drug Registration Certificate for Magnesium, Sodium, and Potassium Sulfate Oral Solution”, “Notice on Subsidiaries Obtaining a Registration Certificate for Donepezil Hydrochloride Oral Drug”, and “Notice on Obtaining a Drug Registration Certificate for Levocarnitine Oral Solution”. 5. On September 1, 2026, the company disclosed the “Notice Concerning Azithromycin Tablets Passing the Conformity Evaluation of Generic Drugs”. 6. The company has found no other important information to be disclosed that may have a significant impact on the company's stock price. 7. After inquiring with the controlling shareholders and actual controllers of the company, there are no important matters relating to the company that should be disclosed but not disclosed or that are in the planning stage. 8. According to inquiries, the controlling shareholder and actual controller did not trade the Company's shares during the period of abnormal fluctuations in the Company's stock trading.